Back to top
more

Baxter International (BAX)

(Delayed Data from NYSE)

$45.69 USD

45.69
5,078,769

+0.55 (1.22%)

Updated Jan 31, 2023 04:00 PM ET

After-Market: $45.71 +0.02 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.28%
2Buy17.83%
3Hold9.19%
4Sell5.00%
5Strong Sell2.16%
S&P50010.51%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 249)

Industry: Medical - Products

Trades from $1

Zacks News

Headquartered in Deerfield, IL, Baxter International Inc. (BAX) is a global medical technology company. However, the company spun off its biopharmaceuticals segment into an independent entity – Baxalta Inc. Following the spinoff, the company consists of renal and hospital products, providing items such as kidney-dialysis equipment, infusion pumps, and intravenous (IV) solutions.

Baxter (BAX) to Report Q4 Earnings: What's in the Cards?

Baxter's (BAX) fourth-quarter results are likely to reflect growth in elective surgical procedures, offset by currency and supply challenges. Hillrom's products are likely to have boosted sales.

Company News for Jan 10, 2023

Companies In The News Are: REGN, LULU, DCT, BAX.

Baxter (BAX) Plans to Form Standalone Kidney Care Company

Baxter (BAX) plans several strategic actions, including spin-off of Renal Care and Acute Therapies global business units into an independent, publicly traded company to simplify its operating model.

Is the Options Market Predicting a Spike in Baxter International (BAX) Stock?

Investors need to pay close attention to Baxter International (BAX) stock based on the movements in the options market lately.

Baxter (BAX) Q3 Earnings Meet Estimates, Hilrom Adds $735 M

Baxter's (BAX) third-quarter results reflect the robust performance of the Medication Delivery business unit and Hilrom's businesses.

Baxter International (BAX) Q3 Earnings Match Estimates

Baxter (BAX) delivered earnings and revenue surprises of 0% and 0.03%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Indrajit Bandyopadhyay headshot

Medical Device Stocks' Q3 Earnings on Oct 27: LH, BIO & More

Medical Device players are likely to have benefited from the reopening of economies and several efforts to combat staffing challenges. Let's see how LH, BIO, BAX, DXCM and WST are likely to fare this time.

MacroGenics (MGNX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

MacroGenics (MGNX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

What's in Store for West Pharmaceutical (WST) in Q3 Earnings?

West Pharmaceutical's (WST) third-quarter results are likely to reflect strength in the Proprietary Products business. However, unfavorable currency movements are likely to hurt the top and bottom lines.

Stryker (SYK) to Report Q3 Earnings: What's in the Cards?

Stryker's (SYK) third-quarter results are likely to reflect strong segmental performances.

Is a Beat Likely for DexCom (DXCM) This Earnings Season?

DexCom's (DXCM) third-quarter results are likely to reflect rising global awareness of its real-time CGM.

Baxter (BAX) to Report Q3 Earnings: Is a Beat in the Cards?

Baxter's (BAX) third-quarter results are likely to reflect growth in its Medication Delivery and Advanced Surgery businesses. Hillrom's products are likely to have boosted sales.

Analysts Estimate Baxter International (BAX) to Report a Decline in Earnings: What to Look Out for

Baxter (BAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 Reasons to Retain Baxter (BAX) Stock in Your Portfolio

Investors remain optimistic about Baxter (BAX) due to its strong product portfolio.

Neogen (NEOG) Q1 Earnings and Revenues Lag Estimates

Neogen (NEOG) delivered earnings and revenue surprises of -6.25% and 2.51%, respectively, for the quarter ended August 2022. Do the numbers hold clues to what lies ahead for the stock?

Baxter (BAX) Novum IQ SYR's FDA Clearance Boosts Patient Care

Latest regulatory approval for Baxter's (BAX) Novum IQ SYR is expected to provide safe and accurate infusions for vulnerable patients.

Baxter (BAX) Q2 Earnings Miss Estimates, Hilrom Adds $715 M

Baxter's (BAX) second-quarter results reflect the robust performance of the Medication Delivery business unit and Hilrom's businesses.

Baxter International (BAX) Misses Q2 Earnings and Revenue Estimates

Baxter (BAX) delivered earnings and revenue surprises of -1.14% and 3.73%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Stryker (SYK) Lags Q2 Earnings and Revenue Estimates

Stryker (SYK) delivered earnings and revenue surprises of -0.88% and 0.78%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Baxter (BAX) to Report Q2 Earnings: What's in the Offing?

Baxter's (BAX) second-quarter results are likely to reflect growth in its Medication Delivery and BioPharma Solutions businesses. Hillrom's products are likely to have boosted sales

3 Reasons to Retain Baxter (BAX) Stock in Your Portfolio

Investors remain optimistic about Baxter (BAX) due to its strong product portfolio.

Should iShares Morningstar MidCap ETF (IMCB) Be on Your Investing Radar?

Style Box ETF report for IMCB

Here's Why You Should Retain Baxter (BAX) Stock For Now

Investors continue to be optimistic about Baxter (BAX) due to its strong product portfolio and regulatory clearances.

Quidel (QDEL) Down 9.8% Since Last Earnings Report: Can It Rebound?

Quidel (QDEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zimmer (ZBH) Down 5.6% Since Last Earnings Report: Can It Rebound?

Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.